• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    K

    Korea Pharma (South Korea)

    企业EST. 1974
    7论文总数
    51引用总数

    论文量&引用量时间轴

    机构学者

    论文(7)

    年份
    起
    –
    止
    排序
    1Implementation of an Interactive Clinical Simulator Based on Facial Anatomy: an Enhanced Model for Injection Training
    Ji-Young Son, Sang-Chul Choi, Hyeong-Seok Choi, Il Kim, Byeong-Ha Kim, Donghun Yang, Seung-Ho Han

    Minimally invasive facial procedures are widely performed in clinical medicine but remain associated with severe complications such as necrosis or blindness, often resulting from insufficient anatomical understanding and limited procedural training. To address these challenges, this study developed an anatomically accurate clinical simulator for facial injection training. A three-dimensional polygonal facial model was constructed using standardized anatomical datasets reflecting skeletal dimensions, soft tissue characteristics and the average arterial distribution of East Asian faces. This model was integrated into simulation software connected to a facial silicone dummy with realistic tissue texture and an optical tracking system providing sub-millimeter precision. Each anatomical structure, including muscles, vessels and nerves, was digitally annotated and linked to interactive visualization tools. During training, the simulator simultaneously reflected the real-time needle trajectory and insertion depth; when the needle tip approached a high-risk structure, such as the supraorbital artery, alerts were automatically triggered. This feedback enabled trainees to recognize unsafe injection zones and adjust their technique accordingly. The system provided a realistic, repeatable and safe environment for improving anatomical comprehension and procedural accuracy. This study proposes an innovative applied simulation system that may enhance medical education and clinical safety in facial injection procedures.

    2025APPLIED SCIENCES-BASEL(2025)
    引用
    AI阅读
    加入学术空间
    2Missing Imputation under Estimand Framework Using Treatment Policy Strategy for Intercurrent Events
    Jaehyuk Kim, Eunjung Song, Siyoen Kil

    This study investigates the impact of missing data and intercurrent events (ICEs) on the validity and efficiency of statistical inference in longitudinal clinical trials, specifically under the ICH E9(R1) estimand framework using the treatment policy strategy. A series of simulation experiments were conducted to evaluate the statistical properties-bias, variability inflation, and power-of various missing data imputation methods, including reference-based imputation (e.g., Jump to Reference [JR], Copy Reference [CR], Copy Increments in Reference [CIR]), last mean carried forward (LMCF), missing at random (MAR), and retrieved dropout (RDO) approaches. The simulation design reflects common settings in anti-hyperglycemic drug development and varies the proportion of ICEs, the post-ICE treatment effect (remainder factor), and the availability of post-ICE data (retrieved dropout rate). The study highlights that the ICE mechanism and the assumed post-ICE treatment effect generally have a stronger influence on power than the choice of imputation method alone. Notably, RDO methods, while well-aligned with the treatment policy strategy, exhibit substantial power loss when the proportion of retrieved dropouts is below 40%, primarily due to variability inflation. These findings underscore the importance of aligning imputation strategies with the estimand of interest and ensuring sufficient post-ICE data collection, particularly when RDO is used in the primary analysis. Practical implications for study planning, analysis, and regulatory alignment are discussed in light of these results.

    2025COMMUNICATIONS FOR STATISTICAL APPLICATIONS AND METHODS(2025)
    引用
    AI阅读
    加入学术空间
    3Diagnosing and Mitigating LLM Failures in Recognizing Culturally Specific Korean Names: an Error-Driven Prompting Framework
    Xiaonan Wang, Gyuri Choi, Subin An, Joeun Kang, Seoyoon Park, Hyeji Choi, Jongkyu Lee,Hansaem Kim

    As large language models (LLMs) improve in understanding and reasoning, they are increasingly used in privacy protection tasks such as de-identification, privacy-sensitive text generation, and entity obfuscation. However, these applications depend on an essential requirement: the accurate identification of personally identifiable information (PII). Compared with template-based PII that follows clear structural patterns, name-related PII depends much more on cultural and pragmatic context, which makes it harder for models to detect and raises higher privacy risks. Although recent studies begin to address this issue, existing work remains limited in language coverage, evaluation granularity, and the depth of error analysis. To address these gaps, this study proposes an error-driven framework that integrates diagnosis and intervention. Specifically, the framework introduces a method called Error-Driven Prompt (EDP), which transforms common failure patterns into executable prompting strategies. It further explores the integration of EDP with general advanced prompting techniques such as Chain-of-Thought (CoT), few-shot learning, and role-playing. In addition, the study constructed K-NameDiag, the first fine-grained evaluation benchmark for Korean name-related PII, which includes twelve culturally sensitive subtypes designed to examine model weaknesses in real-world contexts. The experimental results showed that EDP improved F1-scores in the range of 6 to 9 points across three widely used commercial LLMs, namely Claude Sonnet 4.5, GPT-5, and Gemini 2.5 Pro, while the Combined Enhanced Prompt (CEP), which integrates EDP with advanced prompting strategies, resulted in different shifts in precision and recall rather than consistent improvements. Further subtype-level analysis suggests that subtypes reliant on implicit cultural context remain resistant to correction, which shows the limitations of prompt engineering in addressing a model’s lack of internalized cultural knowledge.

    2025APPLIED SCIENCES-BASEL(2025)
    引用
    AI阅读
    加入学术空间
    4The Evolving Value Assessment of Cancer Therapies: Principles from the Cancer Community.
    Myrto Lee,Anne-Marie Baird, Susan Brown,Russell Clark,Javier Cortes,Giuseppe Curigliano,Andrea Stern Ferris,Ataru Igarashi,Ravindran Kanesvaran,Hugo Larose,Gary Lyman,Luca Pani,

    e13647 Background: Oncology-relevant measures of disease and treatment support earlier detection, accelerated drug development, and inform treatment pathways. To advance access to transformative treatments for people with cancer, especially those for early-stage cancers where medical intervention has the greatest opportunity to impact the course of the disease, the cancer community identified seven principles that support the evolution of value assessment frameworks. Here we summarize the five key principles. Methods: A group of 24 cancer community experts (9 oncologists, 6 patient advocacy leaders, 1 former regulator, 6 former payers, and 4 health economists) from 14 countries came together to discuss and build consensus on oncology-relevant value principles. Over five months, the expert group engaged via surveys, virtual discussion panels, and interviews. Results: The expert group developed seven consensus principles covering two areas: oncology-relevant endpoints to assess the value of treatments; and additional important value components and how they can be integrated into value assessments. The key 5 principles were oncology-relevant endpoints assessing clinical effectiveness, including the following three items. 1) Consider oncology-relevant endpoints, other than Overall Survival (OS), with intrinsic value for decision-making e.g., Event-, Disease-, or Relapse-Free Survival. 2) Continue to build evidence for endpoints that indicate treatment efficacy earlier e.g., pathologic Complete Response. 3) Develop evidence for the next generation of predictive measures that detect and monitor disease, e.g., circulating tumor DNA and Minimal Residual Disease. Additional value components supporting patient access include the following two items. 1) Use managed entry (type of access) agreements supported by ongoing real world evidence collection to help address decision-maker (regulator and Health Technology Assessment body) evidence needs. 2) Routinely use Patient Reported Outcomes (PROs) in value assessments. Conclusions: To achieve the common goal of all cancer community stakeholders—improved outcomes for people with cancer—collaboration across the cancer community is essential to define how value is assessed, especially for early-stage cancer treatments. This is particularly important since mature OS data is not always available during initial decision-making, and decision-makers need to evolve which are the most appropriate endpoints. This supports measuring clinical impact, but also broader social, financial and ethical impact for patients, caregivers, healthcare systems, society, and the economy (not considered in this abstract). To achieve these goals, the expert group recommends: 1) increasing awareness and systematically engaging people with cancer in value assessments, 2) leveraging PROs in those assessments, and 3) further validation in clinical trials of oncology-relevant endpoints that could provide an earlier indication of clinical outcomes.

    2023JOURNAL OF CLINICAL ONCOLOGY(2023)
    引用
    AI阅读
    加入学术空间
    5Preparation and Evaluation of Poly(2-Hydroxyethyl Aspartamide)-Hexadecylamine-iron Oxide for MR Imaging of Lymph Nodes
    Dae Chul Ha,Ha Young Lee, Yeo Won Son,Soon Hong Yuk,Youn Woong Choi,Byung Kook Kwak, Byung Cheol Shin,Cheong-Weon Cho,Sun Hang Cho

    The purpose of this study was to synthesize biocompatible poly(2-hydroxyethyl aspartamide)-C16-iron oxide (PHEA-C16-iron oxide) nanoparticles and to evaluate their efficacy as a contrast agent for magnetic resonance imaging of lymph nodes. The PHEA-C16-iron oxide nanoparticles were synthesized by coprecipitation method. The core size of the PHEA-C16-iron oxide nanoparticles was about 5 to 7 nm, and the overall size of the nanoparticles was around 20, 60, and 150 nm in aqueous solution. The size of the nanoparticles was controlled by the amount of C16. The 3.0-T MRI signal intensity of a rabbit lymph node was effectively reduced after intravenous administration of PHEA-C16-iron oxide with the size of 20 nm. The in vitro and in vivo toxicity tests revealed the high biocompatibility of PHEA-C16-iron oxide nanoparticles. Therefore, PHEA-C16-iron oxide nanoparticles with 20-nm size can be potentially useful as T2-weighted MR imaging contrast agents for the detection of lymph nodes.

    2014Nanoscale research letters(2014)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 7 篇论文

    合作机构(21)

    中兴大学合作论文 2
    科隆大学合作论文 1
    National Cancer Centre Singapore合作论文 1
    梨花女子大学合作论文 1
    意大利科学领域恢复与治疗研究所合作论文 1
    Constellium合作论文 1
    圣詹姆斯大学医院合作论文 1
    Zurich Insurance Group (Switzerland)合作论文 1
    University of Miami Health System合作论文 1
    Swiss Cancer League合作论文 1

    机构统计